ESMO Immuno-Oncology Congress 2019: Abstracts

Abstract submission is now closed.

Abstract submission deadlines

Abstract submission categories

• Biomarker development
• Cell therapy
• Clinical practice
• Therapeutic development
• Tumour microenvironment
• Tumour metabolism
• Miscellaneous

Late-breaking abstracts (LBA)

Late-breaking abstracts may be submitted for high quality, new research findings from randomised phase II or phase III trials with implications for clinical practice or understanding of disease processes.

Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 2 October 2019 will be considered for late-breaking status. The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to the ESMO Immuno-Oncology Congress 2019.

A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline on of 2 October 2019. 

Submitters of preliminary versions receiving approval to proceed must submit the final LBA by 6 November 2019.

Trial in progress abstracts (TiP)

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Immuno-Oncology Congress 2019.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:

• Background
• Trial design

Notes:

• Recruitment must have already begun or have been completed by the abstract submission deadline of 2 October 2019.
• Abstracts including results or preliminary data will be rejected.
• Trial in Progress abstracts will be considered for Poster presentation only.
• Encore TiP abstracts will NOT be accepted.

Abstracts will be reviewed by the ESMO Immuno-Oncology Congress 2019 Scientific Committee and considered on the merits of the scientific and clinical rationale of the trial.

Publication schedule for accepted abstracts

1. Abstracts accepted for presentation at the ESMO Immuno-Oncology Congress 2019 as Proffered Paper (oral presentation), Mini Oral and Poster will be published online on the ESMO website at 12:00 CET on Thursday, 5 December 2019.
2. Late-breaking abstracts will be made public at the start of the official Congress session during which they are presented.
3. The Publication schedule of abstracts and Late-breaking abstracts selected for inclusion in the ESMO Press programme will be available 10 days before the Congress.

Presentation options for accepted abstracts

Presenters may request an outcome based on the following options. The ESMO Immuno-Oncology Congress 2019 Scientific Committee reserves the right to decide which of these session formats will be scheduled during the Congress.

• Proffered Paper – Oral presentation by authors presenting original data of superior quality, followed by expert discussion and perspectives.
• Mini Oral – Short presentation by authors with comment and interactive audience discussion led by invited experts.
• Poster – Display session for review, discussion and questions. Presenting authors must be available for Q&A for 45 minutes to represent their work.

All accepted abstracts will be published in the ESMO Immuno-Oncology Congress 2019 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.

Merit Awards

A restricted number of Merit Awards to the ESMO Immuno-Oncology Congress 2019 are available, upon application, to candidates under the age of 40. Selection will be made by the ESMO Immuno-Oncology Congress 2019 Scientific Committee on a competitive basis from among the accepted abstracts.

More information can be found in the Abstract regulations.